Published in final edited form as:

Chem Sci. 2014 October 1; 5(10): 3770–3776. doi:10.1039/C4SC01348D.

Conformationally Strained *trans*-Cyclooctene with Improved Stability and Excellent Reactivity in Tetrazine Ligation

Ampofo Darko^a, Stephen Wallace^b, Olga Dmitrenko^a, Melodie M. Machovina^c, Ryan A. Mehl^c, Jason W. Chin^b, and Joseph M. Fox^a

^aBrown Laboratory, Department of Chemistry & Biochemistry, University of Delaware, Newark, Delaware 19716, United States

^bMedical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, United Kingdom

^cDepartment of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon 97331, United States

Abstract

Computation has guided the design of conformationally-strained dioxolane-fused *trans*-cyclooctene (d-TCO) derivatives that display excellent reactivity in the tetrazine ligation. A water soluble derivative of 3,6-dipyridyl-*s*-tetrazine reacts with d-TCO with a second order rate k_2 366,000 ($\pm$ 15,000) M⁻¹s⁻¹ at 25 °C in pure water. Furthermore, d-TCO derivatives can be prepared easily, are accessed through diastereoselective synthesis, and are typically crystalline bench-stable solids that are stable in aqueous solution, blood serum, or in the presence of thiols in buffered solution. GFP with a genetically encoded tetrazine-containing amino acid was site-specifically labelled *in vivo* by a d-TCO derivative. The fastest bioorthogonal reaction reported to date [k_2 3,300,000 ($\pm$ 40,000) M⁻¹s⁻¹ in H₂O at 25 °C] is described herein with a cyclopropane-fused *trans*-cyclooctene. d-TCO derivatives display rates within an order of magnitude of these fastest *trans*-cyclooctene reagents, and also display enhanced stability and aqueous solubility.

Introduction

The use of strain energy to enable molecular reactivity is a venerable concept in the field of organic synthesis, and has in recent years become an increasingly important tool for enabling bioorthogonal reactions—those transformations that retain selectivity in a biological context.¹⁻¹² In 2004, Bertozzi and co-workers first described the use of strain to accelerate the rate of the bioorthogonal cycloaddition between alkynes and azides¹³—a transformation that otherwise requires transition metal catalysis.¹⁴⁻¹⁶ Subsequently, strained molecules have been employed as reactive cycloaddition partners across a range of applications where efficient bioorthogonal labeling is required.^{1, 8, 9, 17-21}

[†]Electronic Supplementary Information (ESI) available: Full experimental details, copies of spectral data, kinetic plots, and computational details. See DOI: 10.1039/b000000x/

In 2008, our group developed a photochemical flow-method for producing functionalized *trans*-cyclooctenes (TCO's),²² and subsequently demonstrated that tetrazines combine with *trans*-cyclooctenes with unusually fast rates ($k_2 > 10^3 \text{ M}^{-1}\text{s}^{-1}$) in bioorthogonal reactions.²³ Contemporaneous with our work on TCO, bioorthogonal reactions of tetrazines with norbornenes²⁴ and the Reppe Anhydride²⁵ were described. More recently, cyclopropenes,²⁶⁻³¹ cyclooctynes³²⁻³⁵ and simple terminal alkenes³⁶ have been used as dienophiles in bioorthogonal reactions with tetrazines. Each of these dienophiles offers unique advantages. Still, there remains a high level of interest in *trans*-cyclooctene dienophiles due to their high reactivity, and as such *trans*-cyclooctenes have been used in a range of applications including cellular imaging and nuclear medicine.³⁷⁻⁴²

While simple *trans*-cyclooctene derivatives combine with *s*-tetrazines with very fast rates, several situations have arisen where even faster rates are necessary. Reaction rate is always a premium consideration for applications to nuclear medicine due to the low concentrations and short half-lives intrinsic to radiochemistry.^{40, 43-51} Fast bioorthogonal reactivity is especially important for pretargeted imaging and radioimmunotherapy where the bioconjugation event takes place *in vivo*.⁴³⁻⁴⁸ The development of more highly reactive TCO probes has also proven necessary for applications to intracellular labeling,^{35, 52-57} as tetrazines that display the best long term *in vivo* stability also tend to be less reactive in Diels-Alder reactions. For example, it was possible to genetically encode an electron-rich tetrazine-containing amino acid into proteins such as GFP (**2**, Scheme 1c); however subsequent labelling by 5-hydroxy-*trans*-cyclooctene was limited by sluggish reactivity.⁵⁸

Computation has emerged as an important tool for understanding and predicting the reactivity of bioorthogonal reaction partners.^{29, 34, 59-63} In parallel with studies by van Delft on the strained cycloalkyne, bicyclo[6.1.0]non-4-yn-9-ylmethanol,¹⁸ we described how the reactivity of TCO could be increased through the introduction of conformational strain. (Scheme 1a).⁶² *Ab initio* calculations predicted the lowest energy 'crown' conformation (**1a**) of *trans*-cyclooctene to be 5.6–5.9 kcal/mol lower in energy than the 'half-chair' conformation (**1b**). Recognizing that *trans*-cyclooctenes with *cis*-ring fusions would be forced to adopt strained conformations similar to **1b** (Scheme 1b),^{60, 62} computation was used to design a strained *trans*-cyclooctene (termed "s-TCO") with a *cis*-fused cyclopropane ring that enforces a highly strained half-chair conformation for the eight-membered ring. Transition state calculations with 3,6-diphenyl-*s*-tetrazine predicted that s-TCO would react much faster than the crown conformation of TCO (**1a**) ($G^{\ddagger\dagger} = 3.34 \text{ kcal/mol}$ at 25 °C). Experimentally, s-TCO combined with 3,6-diphenyl-*s*-tetrazine in MeOH at 25 °C with a rate of $3100 \text{ M}^{-1}\text{s}^{-1}$ — 160 times faster than *trans*-cyclooctene (Scheme 1b). The experimentally measured $G^{\ddagger}$ (3.0 kcal/mol) correlated closely with this predicted value. With more reactive tetrazines under aqueous conditions, rates can exceed $10^6 \text{ M}^{-1}\text{s}^{-1}$, making s-TCO the most reactive dienophile reported to date for bioorthogonal applications.^{44, 62, 64} With GFP derivative **2**, fluorogenic labelling by s-TCO takes place rapidly inside living bacteria (Scheme 1c).⁵⁸

While the reactivity of s-TCO in tetrazine ligation is desirable, there are some limitations that also emerge from its high reactivity. As we have discussed previously, s-TCO was found to isomerize in the presence of high thiol concentrations (30 mM), presumably via a

free radical mediated pathway.⁶² Furthermore, many *s*-TCO derivatives tend to be only moderately stable to prolonged storage, and must be kept in cold solution to avoid polymerization and isomerization.⁶⁵ Additionally, *s*-TCO is hydrophobic, and its synthesis is not stereoselective, necessitating chromatographic separation of *syn*- and *anti*- product diastereomers.

For the reasons outlined above, we considered the design of new conformationally strained *trans*-cyclooctene derivatives that would maintain high reactivity toward *s*-tetrazines but display enhanced stability and be more easily prepared. To this end, we considered *cis*-dioxolane-fused *trans*-cyclooctenes (d-TCO) derivatives of structure **3** (Schemes 2 and 3). It was expected that the *cis*-fused ring would enforce a strained half-chair conformation of the cyclooctene, imparting high reactivity toward tetrazines. However, it was also reasoned that the alkene of d-TCO would be less electron rich (and hence more stable) than that of *s*-TCO as a result of the inductively electron withdrawing oxygens. The hope for d-TCO was that a modest compromise in reactivity toward tetrazines would be compensated by enhanced stability. We also projected that the dioxolane functionality would impart improved aqueous solubility for d-TCO.

Our studies began with a computational comparison of the reactions of 3,6-diphenyl-*s*-tetrazine with the crown conformation of *trans*-cyclooctene (**1a**) and that of d-TCO derivative **3a**, which is locked in the half-chair conformation. Transition state calculations in the gas phase between **1a** and 3,6-diphenyl-*s*-tetrazine at the M06L/6(311)+G(d,p) level were described previously, and shown to proceed with a barrier of $E^\ddagger = 13.31$ kcal/mol and $G^\ddagger = 16.09$ kcal/mol (Scheme 2a). By comparison, the computed reaction of 3,6-diphenyl-*s*-tetrazine and d-TCO **3a** proceeds with a significantly lower barrier ($E^\ddagger = 10.82$ kcal/mol and $G^\ddagger = 13.27$ kcal/mol, Scheme 2b). These calculations predict that the reactions of d-TCO would be considerably faster than that of the parent TCO **1**.

Encouraged by this computational prediction, we prepared derivatives of **3a** and **3b** as shown in Scheme 3. The diol **4** can be prepared in multigram quantity from 1,5-cyclooctadiene by Upjohn dihydroxylation.⁶⁶ Diol **4** combined with glycolaldehyde dimer at room temperature to give **5** as a 12:1 mixture in favor of the *syn*-diastereomer. When dioxolane formation was conducted at 80 °C, both *syn*- and *anti*- diastereomers of **5** were produced in a 1:1 ratio. This kinetic preference for the *syn*-diastereomer is known for cyclic acetals,⁶⁷⁻⁶⁹ and has been ascribed to the relief of 1,3 allylic strain⁷⁰ in the cyclization of the oxonium intermediate. Photoisomerization using the closed-loop flow reactor^{22, 71} developed in our labs gave d-TCO **3a** in 59% yield. Likewise, acetal **6** was prepared from adipic semialdehyde methyl ester, and photoisomerized to give d-TCO **3b** in 36% yield, predominantly as the *syn*-diastereomer (>50:1). The brief and diastereoselective nature of the syntheses of d-TCO derivatives greatly facilitates material throughput, as illustrated by a gram-scale preparation of d-TCO **3a**. A conjugatable derivative of **3a** could be prepared by treatment with *p*-nitrophenylchloroformate to give the activated carbonate **7** in 56% yield, and can be readily conjugated to amines under standard conditions using Hunig's base, as demonstrated by the synthesis of biotin-mini-PEG derivative **8** (Scheme 3).

Rate constants for the reaction of d-TCO derivatives with tetrazine derivatives were measured under several conditions (Scheme 4). Diphenyl-*s*-tetrazine with d-TCO **3b** in MeOH (25 °C) reacts with a rate of 520 (+/- 3) M⁻¹s⁻¹. The same tetrazine was found to react with the parent *trans*-cyclooctene with a rate of 19.1 (+/- 1) M⁻¹s⁻¹.⁶² The observed 27-fold rate enhancement ($\Delta G^\ddagger = 2.0$ kcal/mol) for d-TCO is in good alignment with the computationally predicted value ($\Delta G^\ddagger = 2.8$ kcal/mol; ($\Delta E^\ddagger = 2.5$ kcal/mol) described above. To ensure that the rate acceleration for d-TCO was due to the ring fusion, and not due to the electronic influence of the hydroxyl groups, we compared the rate of diphenyl-*s*-tetrazine with diol **9**, which was prepared by photoisomerizing diol **4**. The observed rate constant $k_2 = 41$ (+/- 8.1 × 10⁻²) M⁻¹s⁻¹ was significantly slower than the rate of the d-TCO **3b**. This observation provides strong evidence that the conformational strain of the 8-membered ring is indeed responsible for the observed rate acceleration.

Under aqueous conditions, reactions are significantly faster due to acceleration by the hydrophobic effect, and as such a stopped-flow technique was used to measure rate constants. Previously, a rate of k_2 5235 (+/- 258) M⁻¹s⁻¹ was measured for the equatorial diastereomer of 5-hydroxy-*trans*-cyclooctene (**11**) with tetrazine **10** at 25 °C in 45:55 H₂O:MeOH.³⁵ Under similar conditions, d-TCO **3a** reacts with tetrazine **10** with a rate k_2 167,000 (+/- 7000) M⁻¹s⁻¹. As expected, the fastest rates are measured under purely aqueous conditions. Improved aqueous solubility of the d-TCO derivatives made kinetic measurements in aqueous conditions possible. At 25 °C in water, the *syn*-diastereomer of d-TCO (*syn*-**3a**) combines with the freely water soluble derivative **12** with a rate k_2 366,000 (+/- 15,000) M⁻¹s⁻¹. The *anti*-diastereomer (*anti*-**3a**) combines with a rate k_2 318,000 (+/- 2900) M⁻¹s⁻¹. In a recent study, Robillard reported that the axial diastereomer of 5-hydroxy-*trans*-cyclooctene is more reactive than the equatorial diastereomer.⁴⁴ Under similar conditions, d-TCO derivatives **3a** and **3b** combine with **12** with a rate that is significantly faster than either diastereomer of 5-hydroxy-*trans*-cyclooctene: the axial diastereomer **13** reacts with k_2 80,200 (+/- 200) M⁻¹s⁻¹, and the equatorial diastereomer **11** reacts with k_2 22,600 (+/- 40) M⁻¹s⁻¹. As expected, faster rates were observed with *s*-TCO derivatives. Water soluble *s*-TCO **14** reacts with **12** at a rate of k_2 3,300,000 (+/- 40,000) M⁻¹s⁻¹, which to the best of our knowledge, makes this the fastest conjugation rate measurement to date.

While d-TCO derivatives are extremely reactive toward tetrazines, they also display excellent stability. While *s*-TCO derivatives can be handled as neat materials, for storage we find it is necessary to keep most⁷² *s*-TCO compounds in solution at freezer temperatures. By contrast, the stability of d-TCO derivatives are greatly improved. Both **3a** and **3b** are crystalline solids that can be stored uneventfully on the bench and are soluble ($\log P = 0.94$ for *syn*-**3a**) and stable in aqueous solutions. As a safeguard for long-term storage, these compounds are kept as solids in the freezer (-20 °C), where they are stable for at least 14 months. In phosphate buffered D₂O (pD 7.4), no isomerization or decomposition of *syn*-**3a** (20 mM) was noted after 14 days. In concentrated solution (0.5 M in CD₃OD), *syn*-**3a** and *anti*-**3a** isomerizes very slowly at room temperature, with 5% isomerization after three days. For an 5 mM solution of *syn*-**3a** in human serum at room temperature, no isomerization or decomposition was observed after 24 hours, and the compound was >97% *trans* after 4 days.

In the presence of rabbit reticulocyte lysate (10%) in buffered D₂O (pD 7.4), compound *syn*-**3a** isomerized slowly with 12%, 22% and 41% isomerization after 10, 24 and 96 hours, respectively. The isomerization of *syn*-**3a** in the presence of reticulocyte lysate is possibly a thiol-radical promoted process, as both glutathione and mercaptoethanol were found to promote d-TCO isomerization. Thus, mercaptoethanol (30 mM) promoted isomerization of *syn*-**3a** slowly at pH 6.8 (44% isomerization after 48 hours), and more rapidly at pH 7.4 (43% isomerization after 5 hours). Previously, we noted that s-TCO (Scheme 1b) is susceptible toward isomerization in the presence of thiols,⁶² presumably by a radical mediated process. Robillard has also noted the higher propensity of s-TCO to isomerize *in vivo*.⁷³ While d-TCO appears more robust than s-TCO toward thiol-promoted isomerization, both of these strained TCOs are less resilient than conformationally unstrained TCOs such as **9**.^{74, 75} Full details of isomerization studies are provided in the Supplementary Information.

In a prior study, it was shown that the tetrazine derived amino acid **15** could be site-specifically encoded into proteins such as GFP (**2**) by an evolved *Methanococcus jannaschii* (*Mj*) tyrosyl-tRNA synthetase/tRNA_(CUA) pair (Scheme 5).⁵⁸ When genetically encoded into GFP, this amino acid could be tagged *in vivo* by reactive s-TCO derivatives. Given the advantages of d-TCO in terms of synthesis and stability, we investigated the ability of this dienophile to label protein **2**. As described previously, the tetrazine of **2** quenches the fluorescence of the attached GFP. After tetrazine ligation the fluorescence is restored, thus providing a convenient handle for monitoring the reaction. With d-TCO *syn*-**3a** and **3b**, *in vitro* labelling takes place rapidly with a rate constant of k_2 95 ($\pm$ 0.3) M⁻¹s⁻¹ and k_2 99 ($\pm$ 0.6) M⁻¹s⁻¹ to give conjugates **16a** and **16b**, respectively (Scheme 5a). As expected, labelling by the d-TCOs was much faster than labelling by 5-hydroxy-*trans*-cyclooctene (**13**), and within an order of magnitude of the more reactive s-TCO (Scheme 1b). *In vivo* labelling of **2** with d-TCO *syn*-**3a** was confirmed by mass spectroscopy. Thus, *E. coli* containing expressed **2** were washed and incubated with *syn*-**3a** for 2 h in PBS buffer at room temperature. After washing the cells to remove excess *syn*-**3a**, purification was carried out using His-tagged protein affinity chromatography. Q-TOF MS of the purified protein confirmed the molecular mass of **16a**, thereby successfully demonstrating site-specific labelling *in vivo* (Scheme 5b).

Conclusions

Computation was used to design of conformationally strained dioxolane-fused *trans*-cyclooctene (d-TCO) derivatives that also display excellent reactivity in the tetrazine ligation. The *cis*-dioxolane ring introduces conformational strain and improved aqueous solubility to the cyclooctene derivatives. A water-soluble derivative of 3,6-dipyridyl-s-tetrazine reacts with d-TCO with a second order rate k_2 366,000 ($\pm$ 15,000) M⁻¹s⁻¹ at 25 °C in pure water. d-TCO derivatives can be prepared easily through diastereoselective synthesis, and are typically crystalline bench-stable solids that are stable in aqueous solution, blood serum, or in the presence thiols in buffered solution. GFP with a genetically encoded tetrazine-containing amino acid was site specifically labelled *in vivo* by a d-TCO

derivative. This combination of reactivity and stability make d-TCOs attractive for bioorthogonal applications where fast rates and stability are of importance.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We gratefully acknowledge support of the National Science Foundation (NSF CHE1112409) and National Institutes of Health (R01 EB014354, R01 GM068640-S). For instrumentation support, we thank NIH P20RR017716, NIH S10 RR026962, NSF CHE0840401, CHE- 1229234. This work was also supported by Medical Research Council, UK (grants U105181009 and UD99999908). S.W is the recipient of a Career Development Fellowship from the Medical Research Council.

Notes and references

1. Jewett JC, Bertozzi C. *Chem. Soc. Rev.* 2010; 39:1272–1279. [PubMed: 20349533]
2. Sletten EM, Bertozzi CR. *Angew. Chem. Int. Ed.* 2009; 48:6974–6998. [PubMed: 19714693]
3. Sletten EM, Bertozzi CR. *J. Am. Chem. Soc.* 2011; 133:17570–17573. [PubMed: 21962173]
4. Chalker JM, Bernardes GJL, Davis BG. *Acc. Chem. Res.* 2011; 44:730–741. [PubMed: 21563755]
5. Dirksen A, Dawson PE. *Bioconj. Chem.* 2008; 19:2543–2548. [PubMed: 19053314]
6. Durek T, Alewood PF. *Angew. Chem. Int. Ed.* 2011; 50:12042–12045. [PubMed: 21997950]
7. Lin YA, Chalker JM, Floyd N, Bernardes GJL, Davis BG. *J. Am. Chem. Soc.* 2008; 130:9642–9643. [PubMed: 18593118]
8. Moran J, McKay CS, Pezacki JP. *Can. J. Chem.* 2011; 89:148–151.
9. Sanders BC, Friscourt F. d. r. Ledin PA, Mbua NE, Arumugam S, Guo J, Boltje TJ, Popik VV, Boons G-J. *J. Am. Chem. Soc.* 2010; 133:949–957. [PubMed: 21182329]
10. Song W, Wang Y, Qu J, Lin Q. *J. Am. Chem. Soc.* 2008; 130:9654–9655. [PubMed: 18593155]
11. Stockmann H, Neves AA, Stairs S, Brindle KM, Leeper FJ. *Org. Biomol. Chem.* 2011; 9:7303–7305. [PubMed: 21915395]
12. Noda H, Er s G, Bode JW. *J. Am. Chem. Soc.* 2014 10.1021/ja5018442.
13. Agard NJ, Prescher JA, Bertozzi CR. *J. Am. Chem. Soc.* 2004; 126:15046–15047. [PubMed: 15547999]
14. Kolb HC, Finn MG, Sharpless KB. *Angew. Chem., Int. Ed.* 2001; 40:2004–2021. [PubMed: 11433435]
15. Tornøe CW, Christensen C, Meldal M. *J. Org. Chem.* 2002; 67:3057–3062. [PubMed: 11975567]
16. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. *Angew. Chem. Int. Ed.* 2002; 41:2596–2599. [PubMed: 12203546]
17. Baskin JM, Prescher JA, Laughlin ST, Agard NJ, Chang PV, Miller IA, Lo A, Codelli JA, Bertozzi CR. *Proc. Natl. Acad. Sci.* 2007; 104:16793–16797. [PubMed: 17942682]
18. Dommerholt J, Schmidt S, Temming R, Hendriks LJA, Rutjes FPJT, van Hest JCM, Lefebvre DJ, Friedl P, van Delft FL. *Angew. Chem. Int. Ed.* 2010; 49:9422–9425. [PubMed: 20857472]
19. Tummatorn J, Batsomboon P, Clark RJ, Alabugin IV, Dudley GB. *J. Org. Chem.* 2012; 77
20. Yu Z, Lin Q. *J. Am. Chem. Soc.* 2014; 136:4153–4156. [PubMed: 24592808]
21. Patterson DM, Nazarova LA, Prescher JA. *ACS Chem. Biol.* 2014; 9:592–605. [PubMed: 24437719]
22. Royzen M, Yap GPA, Fox JM. *J. Am. Chem. Soc.* 2008; 130:3760–3761. [PubMed: 18321114]
23. Blackman ML, Royzen M, Fox JM. *J. Am. Chem. Soc.* 2008; 130:13518–13519. [PubMed: 18798613]
24. Devaraj NK, Weissleder R, Hilderbrand SA. *Bioconj. Chem.* 2008; 19:2297–2299. [PubMed: 19053305]

25. Pipkorn R, Waldeck W, Didinger B, Koch M, Mueller G, Wiessler M, Braun K. J. Peptide Sci. 2009; 15:235–241. [PubMed: 19177421]
26. Patterson DM, Nazarova LA, Xie B, Kamber DN, Prescher JA. J. Am. Chem. Soc. 2012; 134:18638–18643. [PubMed: 23072583]
27. Yang J, Šekut J, Cole CM, Devaraj NK. Angew. Chem. Int. Ed. 2012; 51:7476–7479. [PubMed: 22696426]
28. Cole CM, Yang J, Seckute J, Devaraj NK. ChemBioChem. 2013; 14:205–208. [PubMed: 23292753]
29. Kamber DN, Nazarova LA, Liang Y, Lopez SA, Patterson DM, Shih H-W, Houk KN, Prescher JA. J. Am. Chem. Soc. 2013; 135:13680–13683. [PubMed: 24000889]
30. Elliott TS, Townsley FM, Bianco A, Ernst RJ, Sachdeva A, Elsasser SJ, Davis L, Lang K, Pisa R, Greiss S, Lilley KS, Chin JW. Nat. Biotech. 2014; 32:465–472. [PubMed: 24727715]
31. Patterson DM, Jones KA, Prescher JA. Molecular BioSystems. 2014; 10:1693–1697. [PubMed: 24623192]
32. Chen W, Wang D, Dai C, Hamelberg D, Wang B. Chem. Commun. 2012; 48:1736–1738. [PubMed: 22159330]
33. Karver MR, Weissleder R, Hilderbrand SA. Angew. Chem. Int. Ed. 2012; 51:920–922. [PubMed: 22162316]
34. Liang Y, Mackey JL, Lopez SA, Liu F, Houk KN. J. Am. Chem. Soc. 2012; 134:17904–17907. [PubMed: 23061442]
35. Lang K, Davis L, Wallace S, Mahesh M, Cox DJ, Blackman ML, Fox JM, Chin JW. J. Am. Chem. Soc. 2012; 134:10317–10320. [PubMed: 22694658]
36. Niederwieser A, Späte A-K, Nguyen LD, Jüngst C, Reutter W, Wittmann V. Angew. Chem. Int. Ed. 2013; 52:4265–4268. [PubMed: 23468318]
37. Devaraj NK, Weissleder R. Acc. Chem. Res. 2011; 44:816–827. [PubMed: 21627112]
38. Knall A-C, Slugovc C. Chem. Soc. Rev. 2013; 42:5131–5142. [PubMed: 23563107]
39. Niki I, Plass T, Schraidt O, Szymanski J, Briggs JAG, Schultz C, Lemke EA. Angew. Chem. Int. Ed. 2014; 53:2245–2249. [PubMed: 24474648]
40. Selvaraj R, Liu S, Hassink M, Huang C.-w, Yap L.-p, Park R, Fox JM, Li Z, Conti PS. Biorg. Med. Chem. Lett. 2011; 21:5011–5014. [PubMed: 21601452]
41. Selvaraj R, Fox JM. Curr. Opin. Chem. Biol. 2013; 17:753–760. [PubMed: 23978373]
42. Šekut J, Devaraj NK. Curr. Opin. Chem. Biol. 2013; 17:761–767. [PubMed: 24021760]
43. Rossin R, Verkerk P, Renart, van den Bosch SM, Volders RCM, Verel I, Lub J, Robillard MS. Angew. Chem. Int. Ed. 2010; 49:3375–3378.
44. Rossin R, van den Bosch SM, ten Hoeve W, Carvelli M, Versteegen RM, Lub J, Robillard MS. Bioconj. Chem. 2013; 24:1210–1217. [PubMed: 23725393]
45. Zeglis BM, Sevak KK, Reiner T, Mohindra P, Carlin SD, Zanzonico P, Weissleder R, Lewis JS. J. Nucl. Med. 2013; 54:1389–1396. [PubMed: 23708196]
46. Devaraj NK, Thurber GM, Keliher EJ, Marinelli B, Weissleder R. Proc. Natl. Acad. Sci. 2012; 109:4762–4767. [PubMed: 22411831]
47. Keliher EJ, Reiner T, Turetsky A, Hilderbrand SA, Weissleder R. ChemMedChem. 2011; 6:424–427. [PubMed: 21360818]
48. Reiner T, Keliher EJ, Earley S, Marinelli B, Weissleder R. Angew. Chem. Int. Ed. 2011; 50:1922–1925. [PubMed: 21328671]
49. Li Z, Cai H, Hassink M, Blackman ML, Brown RCD, Conti PS, Fox JM. Chem. Commun. 2010; 46:8043–8045. [PubMed: 20862423]
50. Liu S, Hassink M, Selvaraj R, Yap LP, Park R, Wang H, Chen X, Fox JM, Li Z, Conti PS. Mol. Imaging. 2013; 12:121–128. [PubMed: 23415400]
51. Wu Z, Liu S, Hassink M, Nair I, Park R, Li L, Todorov I, Fox JM, Li Z, Shively JE, Conti PS, Kandeel F. J. Nucl. Med. 2013; 54:244–251. [PubMed: 23297075]
52. Devaraj NK, Upadhyay R, Haun JB, Hilderbrand SA, Weissleder R. Angew. Chem. Int. Ed. 2009; 48:7013–7016. [PubMed: 19697389]

53. Devaraj NK, Hilderbrand S, Upadhyay R, Mazitschek R, Weissleder R. *Angew. Chem. Int. Ed.* 2010; 49:2869–2872. [PubMed: 20306505]
54. Carlson JCT, Meimetis LG, Hilderbrand SA, Weissleder R. *Angew. Chem. Int. Ed.* 2013; 52:6917–6920. [PubMed: 23712730]
55. Liu DS, Tangpeerachaikul A, Selvaraj R, Taylor MT, Fox JM, Ting AY. *J. Am. Chem. Soc.* 2011; 134:792–795. [PubMed: 22176354]
56. Plass T, Milles S, Koehler C, Szymanski J, Mueller R, Wießler M, Schultz C, Lemke EA. *Angew. Chem. Int. Ed.* 2012; 51:4166–4170. [PubMed: 22473599]
57. Stockmann H, Neves AA, Day HA, Stairs S, Brindle KM, Leeper FJ. *Chem. Commun.* 2011; 47:7203–7205. [PubMed: 21611648]
58. Seitchik JL, Peeler JC, Taylor MT, Blackman ML, Rhoads TW, Cooley RB, Refakis C, Fox JM, Mehl RA. *J. Am. Chem. Soc.* 2012; 134:2898–2901. [PubMed: 22283158]
59. Liang Y, Mackey JL, Lopez SA, Liu F, Houk KN. *J. Am. Chem. Soc.* 2013; 134:17904–17907. [PubMed: 23061442]
60. Bach RD. *J. Am. Chem. Soc.* 2009; 131:5233–5243. [PubMed: 19301865]
61. Gold B, Dudley GB, Alabugin IV. *J. Am. Chem. Soc.* 2012; 135:1558–1569. [PubMed: 23272641]
62. Taylor MT, Blackman ML, Dmitrenko O, Fox JM. *J. Am. Chem. Soc.* 2011; 133:9646–9649. [PubMed: 21599005]
63. Yu Z, Lin Q. *J. Am. Chem. Soc.* 2014; 136:4153–4156. [PubMed: 24592808]
64. Schoch J, Staudt M, Samanta A, Wiessler M, Jäschke A. *Bioconj. Chem.* 2013; 23:1382–1386.
65. An exception is the nitrophenylcarbonate of s-TCO, a crystalline solid that is bench stable.
66. VanRheenen V, Kelly RC, Cha DY. *Tetrahedron Lett.* 1976; 17:1973–1976.
67. Clode DM. *Chem. Rev.* 1979; 79:491–513.
68. Fujioka H, Nagatomi Y, Kitagawa H, Kita Y. *J. Am. Chem. Soc.* 1997; 119:12016–12017.
69. Reddy PV, Smith J, Kamath A, Jamet H, Veyron A, Koos P, Philouze C, Greene AE, Delair P. *J. Org. Chem.* 2013; 78:4840–4849. [PubMed: 23557153]
70. Hoffmann RW. *Chem. Rev.* 1989; 89:1841–1860.
71. Royzen M, Taylor MT, DeAngelis A, Fox JM. *Chem. Sci.* 2011; 2:2162–2165. [PubMed: 23125911]
72. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. *Circ Res.* 1979; 44:127–137. [PubMed: 363301]
73. Rossin R, van den Bosch SM, Ten Hoeve W, Carvelli M, Versteegen RM, Lub J, Robillard MS. *Bioconjugate chemistry.* 2013; 24:1210–1217. [PubMed: 23725393]
74. In CD₃OD with mercaptoethanol (30 mM), s-TCO (30 mM) isomerized rapidly after an 8 hour induction period, with complete conversion to the cis-isomer after 4 additional hours. In a similar experiment with d-TCO (30 mM), the induction period was 10 hours. After the induction period, there was 42% isomerization after 4 hours, and 92% isomerization after 14 hours.
75. At pH 7.4 in D₂O in the presence of glutathione (10 mM), only 12% isomerization of compound 9 (10 mM) was observed after 8 hours. A similar experiment with *syn*-**3a** showed 53% isomerization after 4 hours, and 92% isomerization after 8 hours.

Scheme 1.

- (a) Conformation analysis of ground states show that the half- chair conformation of TCO is higher in energy by 5.6–5.9 kcal/mol relative to the lowest energy crown conformation. (b) As predicted computationally, the conformationally constrained s-TCO (**1b**) combines with 3,6-diphenyl-*s*-tetrazine in with a rate that is 160 times faster than *trans*-cyclooctene itself. (c) For GFP with a genetically encoded tetrazine-containing amino acid, s-TCO enables rapid fluorogenic labelling inside living bacteria.

Chem Sci. Author manuscript; available in PMC 2015 June 23.

Scheme 3.
Synthesis of d-TCO derivatives

Scheme 4.
 Comparison of second order rate constants

Scheme 5.

Characterization of tetrazine d-TCO reaction on GFP (a) *in vitro* labelling rates of d-TCOs with tetrazine unnatural amino acid derived GFP **2** (b) Q-TOF mass spectrum from the *in vivo* labelling of **syn-3a** and **2**. Near quantitative conversion of **2** with **syn-3a** demonstrating specific conversion to **16a** (expected 28130 Da; observed 28130 ± 1 Da). Each sample did show a small peak at -131 ± 1 Da indicating minor amounts of peptidase-based removal of N-terminal methionines and +22 sodium adducts.